Sponsored by CME LLC for 1.5 Category 1 credits.
Original release date 1/06. Approved for CME credit through 12/31/06.
After reading this article, you will be familiar with:
- The history, physiological effects and mechanism of action of MDMA, ketamine and GHB (club drugs).
- Treatments for reactions to club drugs.
- Efforts at harm reduction among users of club drugs and risk of dependence.
Who will benefit from reading this article?
Psychiatrists, primary care physicians, neurologists, nurse practitioners, psychiatric nurses and other mental health care professionals. Continuing medical education credit is available for most specialties. To determine if this article meets the CE requirements for your specialty, please contact your state licensing board.
Dr. McDowell is assistant clinical
professor at Columbia
University. He is the
senior medical director of the Substance Treatment and Research Service (STARS)
and director of the Buprenorphine Program. He
maintains a private practice in Manhattan
and has been researching and writing about club drugs for over 12 years.
Dr. McDowell has indicated he has
nothing to disclose.
Club drugs are also called "party drugs," and this name conveys the
commonality and situational nature of their use. They consist of a disparate
group of psychoactive substances and usually include, but are not limited to, 3,4-methylenedioxymethamphetamine (MDMA), ketamine
and g-hydroxybutyrate (GHB). The drugs differ in
terms of administration, mechanism of action and effect. The use of these
substances is by no means limited to parties and large gatherings, but it is
there that they are most often found and best understood.
Club drugs have been linked inextricably with the rise of the rave
phenomenon. Anecdotal reports suggest that raves were "born" in Ibiza, an
island off the coast of Spain
(Bellis et al., 2000). Raves have periodically been
considered "the next big thing" episodically, but have developed into a
background subculture. However, raves remain a locus where young people are
introduced to and use drugs of all kinds and club drugs in particular.
1. Ajaelo I, Koenig K, Snoey
E (1998), Severe hyponatremia
and inappropriate antidiuretic hormone secretion
following ecstasy use. Acad Emerg
2. Beck J (1990), The public health implications of
MDMA use. In: Ecstasy: The Clinical, Pharmacological and Neurotoxicological
Effects of the Drug MDMA, Peroutka SJ, ed. Boston: Klewer Academic, pp77-103.
3. Beck J, Rosenbaum M (1994), Pursuit of Ecstasy: The MDMA Experience. Albany, N.Y.: State University
of New York
4. Bellis MA, Hale G, Bennett A et al. (2000), Ibiza uncovered: changes in substance use and sexual behaviour amongst young people visiting an international
night-life resort. Int J Drug Policy 11(3):235-244.
5. Buffum J, Moser C (1986), MDMA and human sexual
function. J Psychoactive Drugs 18(4):355-359.
6. Burgess C, O'Donohoe A, Gill M (2000), Agony and
ecstasy: a review of MDMA effects and toxicity. Eur
7. Chin MY, Kreutzer RA, Dyer JE (1992), Acute poisoning from gamma-hydroxybutyrate in California.
West J Med 156(4):380-384.
8. Cohen R (1998), The Love Drug: Marching to the Beat
of Ecstasy. Binghamton, N.Y.: Hayworth Press.
9. Curran HV, Monaghan L (2001), In and out of the K-hole: a comparison of the
acute and residual effects of ketamine in frequent
and infrequent ketamine users. Addiction
10. Dalgarno PJ, Shewan D
(1996), Illicit use of ketamine
J Psychoactive Drugs 28(2):191-199.
11. Demirkiran M, Jankovic
J, Dean JM (1996), Ecstasy intoxication: an overlap between serotonin syndrome
and neuroleptic malignant syndrome. Clin Neuropharmacol
12 . Eisner B (1968), Ecstasy: The MDMA Story. Boston: Little, Brown.
13. Eisner B (1993), Ecstasy: The MDMA Story, 2nd ed. Berkeley, Calif.:
14. Fox HC, Parrott AC, Turner JJ (2001), Ecstasy use: cognitive deficits
related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15(4):273-281.
15. Gallimberti L, Canton G, Gentile N et al. (1989), Gamma-hydroxybutyric
acid for treatment of alcohol withdrawal syndrome. Lancet
16. Galloway GP, Frederick SL, Staggers FE Jr et al.
(1997), Gamma-hydroxybutyrate: an emerging drug of
abuse that causes physical dependence. Addiction 92(1):89-96 [see comment].
17. Gay Men's Health Crisis (1997), Drugs in Partyland
[Brochure]. New York:
18. Graeme KA (2000), New drugs of abuse. Emerg Med Clin North Am
19. Green AR,
Cross AJ, Goodwin GM (1995), Review of the pharmacology and clinical
pharmacology of 3,4-methylenedioxymethamphetamine
(MDMA or "Ecstasy"). Psychopharmacology (Berl)
20. Hechler V, Goebaille S,
Maitre M (1992), Selective distribution pattern of gamma-hydroxybutyrate
receptors in the rat forebrain and mid-brain as revealed by quantitative
autoradiograph. Brain Research 572:345-348.
21. Hermle L, Spitzer M, Borchardt
D et al. (1993), Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8(2):171-176.
22. Holland J,
ed. (2001), Ecstasy: The Complete Guide: A Comprehensive Look at the Risks and
Benefits of MDMA. Rochester,
Park Street Press.
23. Jansen KL, Darracot-Cankovic R (2001), The nonmedical use of ketamine, part two: a review of problem use and dependence.
J Psychoactive Drugs 33(2):151-158.
24. Kalant H (2001), The
pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ
SC, Rogers PD, Rajasingham CR (2002), MDMA ('ecstasy') and other 'club
drugs'. The new epidemic. Pediatr
Clin North Am 49(2):415-433.
26. Krystal JH, Karper LP, Seibyl JP et al. (1994), Subanesthetic
effects of the noncompetitive NMDA antagonist, ketamine,
in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine
responses. Arch Gen Psychiatry 51(3):199-214.
27. Lee SJ, Galanter M, Dermatis
H, McDowel D (2003), Circuit parties and patterns of
drug use in a subset of gay men. J Addict Dis
28 . Li J, Stokes S, Woeckener A (1998), A tale of novel intoxication: a review of the effects of
gamma-hydroxybutyric acid with recommendations for
management. Ann Emerg Med 31(6):729-736 [see
29. Liester MB, Grob CS,
Bravo GL, Walsh RN (1992), Phenomenology and sequelae
of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis
180(6):345-352; discussion pp353-354.
30. Malhotra AK, Pinals DA, Weingartner H et al. (1996), NMDA receptor function and
human cognition: the effects of ketamine in healthy
volunteers. Neuropsychopharmacology 14(5):301-307.
31. McCabe ER, Layne EC, Sayler DF et al. (1971),
Synergy of ethanol and a natural soporific-gamma hydroxybutyrate.
32. McCann UD, Eligulashvili V, Ricuarte GA
(2000), (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced
serotonin neurotoxicity: clinical studies. Neuropsychobiology 42(1):11-16.
33. McCann UD, Ricaurte
GA (1993), Reinforcing subjective
effects of (+/-)3,4-methylenedioxymethamphetamine ("ecstasy")
may be separable from its neurotoxic actions:
clinical evidence. J Clin Psychopharmacol
34. McCann UD, Slate SO, Ricaurte GA
(1996), Adverse reactions with 3,4-methylenedioxymethamphetamine
(MDMA; 'ecstasy'). Drug Saf 15(2):107-115.
35. McDowell D, Kleber H (1994), MDMA: its history and
pharmacology. Psychiatr Ann 24:127-130.
36. Montoya AG, Sorrentino R, Lukas SE, Price BH
(2002), Long-term neuropsychiatric consequences of "ecstasy"
(MDMA): a review. Harv Rev Psychiatry 10(4):212-220.
37. Moretti RJ, Hassan SZ,
Goodman LI, Meltzer HY (1984), Comparison of ketamine
and thiopental in healthy volunteers: effects on mental status, mood, and
personality. Anesth Analg
38. Morgan MJ (2000), Ecstasy (MDMA): a review of its possible persistent
psychological effects. Psychopharmacology (Berl)
SP, Kumar SM (1980), Low dose intravenous infusion technique with ketamine. Amnesic, analgesic and sedative
effects in human volunteers. Anaesthesia
40. Peroutka S, ed. (1990), Ecstasy: The Clinical,
Pharmacological and Neurotoxicological Effects of the
Drug MDMA. Boston:
41. Peroutka SJ, Newman H, Harris H (1988), Subjective
effects of 3,4-methylenedioxymethamphetamine in
recreational users. Neuropsychopharmacology
42. Rodgers J (2000), Cognitive performance amongst recreational users of "ecstasy."
Psychopharmacology (Berl) 151(1):19-24.
43. Schwartz RH, Miller NS (1997), MDMA (ecstasy) and the rave: a review.
44. Shannon M (2000), Methylenedioxymethamphetamine
(MDMA, "Ecstasy"). Pediatr Emerg
45 . Shulgin A (1990), History of MDMA. In: Ecstasy:
The Clinical, Pharmacological and Neurotoxicological
Effects of the Drug MDMA, Peroutka SJ, ed. Boston: Klewer Academic, pp1-20.
46. Shulgin AT (1986), The
background and chemistry of MDMA. J Psychoactive Drugs 18(4):291-304.
47. Siegel RK (1984), The natural history of
hallucinogens. In: Hallucinogens: Neurochemical,
Behavioral, and Clinical Perspectives, Jacobs BL, ed. New York: Raven Press,
48. Sprague JE, Everman SL, Nichols DE (1998), An
integrated hypothesis for the serotonergic axonal
loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology
49. Takahara J, Yunoki S, Yakushiji W et al. (1977), Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin
50. Tunnicliff G, Raess BU (2002), Gamma-Hydroxybutyrate (orphan medical). Curr Opin Investig
51. Turner JJ, Parrott AC (2000), 'Is MDMA a human neurotoxin?':
diverse views from the discussants. Neuropsychobiology
52. Verkes RJ, Gijsman HJ, Pieters MS et al. (2001), Cognitive performance and serotonergic function in users of ecstasy.
Psychopharmacology (Berl) 153(2):196-202.
53. Vickers MD (1969), Gammahydroxybutyric acid. Int Anesthesiol Clin 71(1):75-89.
54. Watson L, Beck J (1986), New age seekers: MDMA use
as an adjunct to spiritual pursuit. J Psychoactive Drugs 23(3):261-270.
55. Weir E (2000), Raves: a review of the culture, the drugs and the prevention
of harm. CMAJ 162(13):1843-1848 [see comments].
56. Winstock AR, Griffiths P, Stewart D (2001), Drugs and the dance
music scene: a survey of current drug use patterns among a sample of dance
music enthusiasts in the UK.
Drug Alcohol Depend 64(1):9-17.